

Sample ID: **ACTN01029999T** | Gender: **Male** | Birth year: **1950** | WHO: **1**Tumor: **Skin - Melanoma** | Lesions: **Abdominal, CNS, Liver, Lung** | Stage: **IV**

Summary

Patient clinical history (10-Apr-2022)

| | |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| Relevant systemic treatment history | Vemurafenib (4/2021), Ipilimumab (2022) |
| Other oncological history | Resection (2020) Previous primary tumor: Bone/Soft tissue Schwannoma (4/2019, considered active) |
| Relevant non-oncological history | Pancreatitis, Myocardial infarction |

Molecular results

| | |
|-------------------------------------|------------------------|
| Previous relevant molecular results | ERBB2 3 + (IHC) |
|-------------------------------------|------------------------|

WGS molecular results (15-Apr-2022)

| | |
|-------------------------------------------------------------------|------------------------------|
| Biopsy location | Liver |
| Events with approved treatment evidence in general | BRAF V600E, High TML |
| Events with trial eligibility in local database | BRAF V600E, High TML |
| Additional events with trial eligibility in NL (external) | None |
| Additional events with experimental evidence (general) | None |
| Additional events with off-label experimental evidence in general | None |
| Events with resistance evidence in general | BRAF V600E: Erlotinib |

Approved treatments considered eligible

| |
|--------------------|
| Treatment |
| Not yet determined |

local trials that are open and considered eligible (1)

| Trial | Acronym | Cohort | Molecular | Warnings |
|--------------|--------------|----------|-----------|----------|
| Test Trial 1 | TEST-TRIAL-1 | Cohort B | No | None |

external trials potentially eligible based on molecular results

| Event | Trials |
|------------|---------|
| BRAF V600E | Trial 1 |
| High TML | Trial 1 |

ACTIN Report

PATIENT
ACTN-01-02-9999

REPORT DATE
20-Apr-2022

Molecular Details (WGS)

General

| Purity | Reliable Quality | Predicted tumor origin | TML Status | MS Stability | HR Status | DPYD |
|--------|------------------|------------------------|------------|--------------|------------|--------|
| 98% | Yes | Melanoma (100%) | High (185) | Stable | Proficient | 1* HOM |

Drivers

| Type | Driver | Driver likelihood | Actionable in local | Actionable in external | Best evidence in general | Resistance in general |
|--------------------|---------------------------|-------------------|---------------------|------------------------|--------------------------|-----------------------|
| Mutation (Hotspot) | BRAF p.V600E (4/6 copies) | High | Yes | Yes | Approved | Known |
| Loss | PTEN del | | No | No | | |

Clinical Details

Patient current details (10-Apr-2022)

| | |
|--------------------------------------|-------------------------------------------------|
| Unresolved toxicities grade => 2 | Fatigue (2), Dizziness |
| Significant aberration on latest ECG | Atrial arrhythmia |
| Cancer-related complications | Ascites |
| Known allergies | Wasps (Environment), Pembrolizumab (Medication) |
| Recent surgeries | 21-Mar-2022 |

Tumor details (10-Apr-2022)

| | |
|---------------------|------------------------|
| Measurable disease | Yes |
| CNS lesion status | CNS (active) |
| Brain lesion status | No known brain lesions |

Laboratory results (10-Apr-2022)

| | | | |
|-----------------|-----------------|--------------------|----------------------------------------------------------------|
| Liver function | Total bilirubin | | |
| | ASAT | (< 33 U/L) | 36 U/L (no trend information available) |
| | ALAT | | |
| | ALP | | |
| | Albumin | | |
| Kidney function | Creatinine | | |
| | CKD-EPI eGFR | (> 100 mL/min) | > 100 mL/min (21-Mar-2022) |
| Other | Hemoglobin | (6.5 - 9.5 mmol/L) | 5.5 mmol/L (no trend information available) |
| | Thrombocytes | (155 - 350 10^9/L) | 150 10^9/L (out of range for 2 cons. measurements, trend down) |
| | LDH | (< 245 U/L) | 240 U/L (31-Mar-2022) |

Medication details

| Medication | Categories | Start date | Stop date | Active? | Dosage | Frequency |
|------------|------------|-------------|-------------|---------|---------------|-----------|
| Ibuprofen | NSAIDs | 21-Mar-2022 | 05-May-2022 | Yes | 750 - 1000 mg | 1 / day |

Blood transfusions

| Product | Date |
|-------------------------|-------------|
| Thrombocyte concentrate | 05-Apr-2022 |

Trial Matching Summary

local trials that are closed but considered eligible (0)

| Trial | Acronym | Cohort | Molecular | Warnings |
|-------|---------|--------|-----------|----------|
| None | | | | |

local trials not considered eligible (3)

| Trial | Acronym | Cohort | Open | Ineligibility reasons |
|--------------|--------------|----------|------|-----------------------|
| Test Trial 1 | TEST-TRIAL-1 | Cohort A | Yes | fail general |
| Test Trial 1 | TEST-TRIAL-1 | Cohort C | Yes | Cohort blacklisted |
| Test Trial 2 | TEST-TRIAL-2 | | Yes | fail general |

Trial Matching Details

Potentially eligible trials & cohorts

Test Trial 1

| | |
|----------------------|------------------------------------|
| Potentially eligible | Yes |
| Acronym | TEST-TRIAL-1 |
| Title | This is the first ACTIN test trial |

| Rule | Reference | Evaluation |
|------|------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| I-01 | Is adult | PASS pass specific |
| E-01 | This rule has 2 conditions: 1. Patient has no active brain metastases. 2. Patient has exhausted SOC. | NOT_EVALUATED not evaluated specific |

Test Trial 1 - Cohort A

| | |
|----------------------|-----|
| Cohort ID | A |
| Potentially eligible | No |
| Open for inclusion? | Yes |

| Rule | Reference | Evaluation |
|------|------------------------------|-----------------------|
| I-02 | Has no active CNS metastases | FAIL fail specific |

Test Trial 1 - Cohort B

| | |
|----------------------|-----|
| Cohort ID | B |
| Potentially eligible | Yes |
| Open for inclusion? | Yes |

Test Trial 1 - Cohort C

| | |
|------------------------------|-----|
| Cohort ID | C |
| Potentially eligible | No |
| Open for inclusion? | Yes |
| Blacklisted for eligibility? | Yes |

Other trials & cohorts

Test Trial 2

| | | |
|----------------------|-------------------------------------|---------------|
| Potentially eligible | No | |
| Acronym | TEST-TRIAL-2 | |
| Title | This is the second ACTIN test trial | |
| Rule | Reference | Evaluation |
| I-01 | Should have active infection | FAIL |
| | | fail specific |